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ABSTRACT 
Gastrointestinal absorption of several ß-blockers is inhibited by citrus juices, 
although molecular mechanism(s) lying on their small intestinal absorption has not yet 
been identified. Here, we attempted to demonstrate involvement of both influx and 
efflux transporters in vivo in gastrointestinal absorption of celiprolol in mice. Plasma 
concentration of celiprolol (3 mg/kg) after oral administration was mostly under the 
limit of quantification in wild mice, whereas that in mdr1a/b knockout (mdr1a/b(-/-)) 
mice was much more obvious, indicating P-glycoprotein-mediated efflux. Then, the oral 
absorption of celiprolol in mdr1a/b(-/-) mice was further examined to investigate influx 
transport mechanism with avoiding effect of P-glycoprotein. Coadministration of 
bromosulfophthalein (BSP), an inhibitor of various influx transporters including organic 
anion transporting polypeptide (OATP) reduced plasma celiprolol concentration. 
Inhibition by BSP of celiprolol uptake from apical membranes was confirmed in 
Ussing-type chamber of small intestinal tissues. Uptake of celiprolol by human small 
intestinal transporter OATP-A/1A2 was also confirmed in Xenopus Laevis oocytes. 
Interestingly, OATP-A/1A2 accepts various ß-blockers including acebutolol, atenolol 
and sotalol, oral absorption of which is inhibited by coadministration of citrus juice or 
telithromycin in human. Taken together, these findings have suggested fundamental role 
of influx transport system(s) in oral absorption of celiprolol. 
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INTRODUCTION 
ß-blockers have been clinically used for the treatment of various types of 
cardiovascular diseases including hypertension, myocardial infarction, angina pectoris 
and arrhythmia. They are also recently prescribed for chronic heart failure, although 
such application is still under the clinical trial in Japan 1,2. In most cases, ß-blockers are 
orally administered to the patients because of their adequate absorption. The mechanism 
for the gastrointestinal absorption of ß-blockers has not yet been fully identified, but the 
earlier research done by Taylor et al. (1985) has proposed two different types of 
absorption mechanism for hydrophilic (atenolol, nadolol, practolol and sotalol with logP 
values from -0.79 to 0.76) and lipophilic (alprenolol, metoprolol, oxprenolol, pindolol, 
propranolol and timolol with logP values from 1.75 to 3.65) ß-blockers: The absorption 
rate constant for hydrophilic ones is almost identical among the compounds, whereas 
that for lipophilic ones depends on octanol-water partition and is consistent with 
pH-partition theory 3.  
The unique properties in gastrointestinal absorption of ß-blockers include 
possible involvement of efflux transporter(s) in their small intestinal absorption. 
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Bioavailability in human of acebutolol and celiprolol increases as the increase in dose 4,5, 
probably due to the saturation of the efflux transport system in small intestine.  
Identification of the active efflux systems for ß-blockers in small intestine was first 
proposed in our laboratory by the previous observation that cyclosporine A, an inhibitor 
for P-glycoprotein (P-gp) increased absorption rate constant of several ß-blockers 
including acebtolol, atenolol, celiprolol and nadolol in rat in situ jejunum loop 6. Among 
the ß-blockers, celiprolol is one of the best characterized P-gp substrates and has also 
been suggested to be actively pumped out by P-gp in rat small intestine 7 and human 
intestinal Caco-2 cells 8-10. In human, oral absorption of celiprolol was reported to 
increase by itraconazole 11, and this effect could be accounted for by the inhibition of 
efflux transport system, possibly P-gp, if we consider minor contribution of metabolism 
to systemic elimination of celiprolol.  
On the other hand, recent clinical investigations have clarified that grapefruit 
juice decreased oral absorption of acebutolol, atenolol, celiprolol and talinolol 11-14. Oral 
absorption of atenolol and celiprolol was also reduced by orange juice 13,15. 
Coadministration of therapeutic agents including verapamil and telithromycin has also 
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been reported to reduce oral bioavailability of talinolol and sotalol, respectively 16,17. 
One of feasible hypotheses may be that a certain constituents in the juice inhibits uptake 
process of these ß-blockers from apical side in the small intestinal epithelial cells, 
although such drug-food interactions may also be explained by other possibilities 
including inhibitory effect on gastric emptying rate and/or lowering effect on intestinal 
pH, leading to decrease in unionized form of ß-blockers. Possible involvement of the 
influx transporters has already been suggested for gastrointestinal absorption of 
fexofenadine, which could be mediated by organic anion transporting polypeptide 
(OATP)-A (OATP1A2) 18,19, although the influx transporters for ß-blockers has not yet 
been identified. 
The drug-food interaction for ß-blockers decreases their systemic exposure 
after oral administration. Therefore, molecular identification of intestinal transporter(s) 
responsible for the oral absorption should be important to avoid any unexpected 
drug-drug or drug-food interaction. However, limited information is available especially 
on influx transporters for ß-blockers from apical membranes in small intestine. The 
purpose of the present study is to demonstrate involvement of influx (uptake) 
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transporter(s) for celiprolol, since inhibitory effect of grapefruit juice on oral absorption 
of celiprolol was most obviously reported among the ß-blockers 11-14. After oral 
absorption, celiprolol is mainly excreted into urine as an unchanged form 1,20,21, 
suggesting minor contribution of metabolism to the systemic elimination. Kirby and 
Unadkat (2007) have already referred to in vitro data for celiprolol and talinolol being 
substrates for influx and efflux transporters in humans 22. However, there has been no 
direct demonstration regarding the involvement of both types of transporters in human 
small intestine possibly due to the limited availability of experimental systems in 
humans. On the other hand, the present study was aimed to use experimental animals to 
demonstrate the involvement of transporters in small intestinal tissues. For such purpose, 
involvement of the efflux transporter (such as P-gp) in small intestine may hinder the 
analysis of influx transporter since inhibition of the efflux transporter may compensate 
the inhibition of influx transporters. Then, the mdr1a/b(-/-) mice were further used to 
focus on the influx transporter(s) for celiprolol to avoid any interference by P-gp. To 
demonstrate involvement of influx transporter(s) in small intestine, 
bromosulfophthalein (BSP) was used as an inhibitor of various influx transporters 
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including OATP in both in vivo and Ussing-type chamber system. To further clarify 
possible involvement of influx transporters, uptake of celiprolol and other ß-blockers 
was demonstrated and characterized in Xenopus laevis oocytes expressing human 
intestinal transporters OATP-A and OATP-B (OATP2B1), both of which are the influx 
transporters localized on apical membranes of human small intestine 19,23. 
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MATERIALS AND METHODS 
Materials 
Celiprolol hydrochloride was gifts from Nichi-iko Pharmaceutical Co., Ltd. 
(Toyama, Japan). [3H]Estrone-3-sulfate (E3S) ammonium salt (1.59 TBq/mmol) was 
purchased from PerkinElmer Life and Analytical Sciences, Inc. (Boston, MA).  The 
pcDNA3 vector was obtained from Invitrogen (Carlsbad, CA). FITC-dextran with an 
average molecular weight of 4,000 (FD-4) was purchased from Sigma-Aldrich Inc. (St. 
Louis, MO). All other reagents were commercial products of reagent grade. 
 
Animals 
 Six- to eight-week old male FVB/NJcl and mdr1a/b knockout mice were 
purchased from CLEA Japan Inc. (Tokyo, Japan) and Taconic Farms Inc. (Germantown, 
NY, USA), respectively. All animal experiments were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee of Kanazawa 
University.  
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Pharmacokinetic Studies 
Mice were fasted overnight with free access to water and anesthetized with diethylether 
during drug administration. Celiprolol (3.0 mg/5 mL/kg body weight) alone, or with 
BSP (30 mg/5 mL/kg body weight) dissolved in saline was orally administered by 
gavage, the concentration of each compound in the dosing solutions being 1.58 and 7.16 
mM, respectively. At various intervals up to 360 min after administration, aliquots of 
about 20 µL of blood were collected through the caudal vein. All blood samples were 
immediately centrifuged to obtain plasma. The plasma samples (8 µL) were mixed with 
sterile distilled water containing of acebutolol as an IS (16 µL) and acetonitrile (32 µL). 
All the mixed solutions were centrifuged at 19,000 g for 15 min at 4°C. The 
supernatants were diluted with an equal volume of mobile phase and centrifuged at 
19,000 g for 15 min at 4°C. The supernatants were subjected to LC-MS/MS analysis. 
 
Transport experiments in Ussing-type chamber 
Intestinal tissue sheets were prepared as described previously 24. The muscle 
layer was removed with fine tweezers and vertically mounted in Ussing-type chambers 
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that provided an exposed area of 0.25 cm2. The volume of bathing solution on each side 
was 1.2 mL, and the solution temperature was maintained at 37 °C in a water-jacketed 
reservoir. The test solution was composed of 128 mM NaCl, 5.1 mM KCl, 1.4 mM 
CaCl2, 1.3 mM MgSO4, 21 mM NaHCO3, 1.3 mM KH2PO4, 10 mM NaH2PO4 and 5 
mM D-glucose (adjusted at pH 6.0 or 7.4 for apical or basal side, respectively), and 
gassed with 95% O2/5% CO2 before and during the transport experiment. The pH value 
at the luminal side in Ussing-type chamber was set to be 6.0 according to our previous 
studies 24-26. The concentration of celiprolol and FD-4 in the apical side was set to be 
100 µM. At the designated times, a 250 µL aliquot of basal side buffer was sampled and 
replaced with an equal volume of fresh buffer. The apical side buffer was also collected 
after finish of the incubation. To determine the concentration of celiprolol, the sample 
solutions (20 μL) were mixed with mobile phase containing of timolol as an IS (20 μL) 
and acetonitrile (40 μL). All the mixed solutions were centrifuged at 19,000 g for 15 
min at 4°C. After centrifugation, the supernatants (70 μL) were dried under nitrogen at 
55°C. The residues were reconstituted with mobile phase (70 μL) and centrifuged at 
19000 g for 15 min at 4°C. The supernatants were subjected to LC-MS/MS analysis. 
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The sample solutions (150 μL) were diluted with sterile distilled water (150 μL). FD-4 
concentrations in samples were determined by a spectrofluorometer (Spectrafluor Plus, 
Tecan Group Ltd., Zurich, Switzerland) at excitation and emission wavelength of 485 
and 535 nm, respectively. 
 
Uptake study with Xenopus laevis oocytes transfected with cRNA encoding 
OATP-A 
 The full-length cDNA of OATP-A was purchased from GenoMembrane, Inc. 
(Kanagawa, Japan) and subcloned into EcoRV and Xho I sites of pcDNA3. The 
full-length cDNA of OATP-B was previously obtained 27 and subcloned into HindIII 
site of pGEMHE vector (kind gift from Prof. Takaaki Abe in Tohoku University 
Graduate School of Medicine). The capped cRNA of OATP-A was synthesized by 
means of a mCAPTM RNA capping kit (Stratagene, La Jolla, CA). Xenopus laevis 
oocytes were prepared and injected with 50 nL of cRNA (25 ng) or water as described 
previously 28. Three days after the cRNA injection, the oocytes were transferred to 
ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 6H2O, 5 mM 
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HEPES, pH 7.4) and pre-incubated at 25˚C for 15 min. Uptake was initiated by 
replacing the solution with fresh ND96 solution with 5 mM MES instead of HEPES (pH 
6.0) at 25°C containing each test compounds. In the cassette dosing studies, the oocytes 
injected with cRNA for OATP-A or water alone were incubated with a mixture of 50 
µM of celiprolol, acebutolol, atenolol, nadolol and sotalol, 1 µM of labetalol and 
oxprenolol, and 0.1 µM of alprenolol, metoprolol, pindolol and propranolol. To assess 
the concentration dependence of celiprolol uptake, oocytes were incubated with 1~3000 
µM of celiprolol. At the designated times, the oocytes were rinsed five times with 
ice-cold ND96 solution. Individual oocytes were added with 50% methanol containing 
of timolol as an IS (35 µL) and acetonitrile (35 µL). The samples were then disrupted 
with a tip sonicator and the lysate was cleared at 15,000g for 15 min at 4°C. The 
supernatants were diluted with an equal volume of sterile distilled water and centrifuged 
at 19,000 g for 15 min at 4°C. The supernatants were subjected to LC-MS/MS analysis. 
Similarly, the oocytes injected with cRNA for OATP-A, OATP-B or water alone were 
incubated with 1.0 µM of celiprolol or 9.4 nM of [3H]E3S (positive control). The uptake 
of [3H]E3S was determined as the radioactivity associated with the oocytes in a liquid 
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scintillation counter, LSC-5100 (Aloka, Tokyo, Japan) with Clearsol I (Nacalai Tesque, 
Inc., Kyoto, Japan) as the scintillation fluid. 
 
Measurement of celiprolol by LC-MS/MS analysis 
Celiprolol was measured with a LC/MS/MS system equipped with a constant 
flow pump (Agilent 1200 series G1312A, Agilent Technologies, Tokyo, Japan), an 
automatic sample injector (G1367B; Agilent Technologies), a column oven (G1316A; 
Agilent Technologies) and a mass spectrometer (API 3200, Applied Biosystems, Tokyo, 
Japan). In pharmacokinetic study, the analytical column was COSMOSIL® AR-II (2.0 
mm x 150 mm; Nacalai Tesque, Kyoto, Japan). The mobile phase consisted of 18:82 
(v/v) methanol and 0.1% formate. Chromatography was isocratically performed at a 
flow rate of 0.2 mL/min at 40°C. The analytes were detected by a tandem mass 
spectrometer (MS/MS) with a TIS interface in positive ionization mode. The multiple 
reaction monitor was set at 337.2 to 116.0 m/z for acebutolol and 380.3 to 74.0 m/z for 
celiprolol. In Ussing-type chamber and oocyte studies, the analytical column was 
COSMOSIL® MS-II (2.0 mm x 50 mm; Nacalai Tesque, Kyoto, Japan). The mobile 
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phase A was 0.01 M ammonium formate and the mobile phase B was methanol. The 
gradient elution time program was set as follows: 0-2 min, B 7-70%; 2-10 min, B, 70%; 
10.1-20 min, B, 7%. The flow rate was 0.2 mL/min. Separation was performed at 40 °C. 
The multiple reaction monitor was set at 337.2 to 116.0, 250.3 to 116.1, 267.2 to 145.0, 
380.3 to 74.0, 329.3 to 162.0, 266.3 to 72.1, 310.3 to 254.3, 266.3 to 72.0, 249.3 to 
116.1, 260.2 to 116.3, 273.1 to 132.8 and 317.2 to 261.0 m/z for acebutolol, alprenolol, 
atenolol, celiprolol, labetalol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, 
sotalol and timolol, respectively. 
 
Statistical Analysis and Calculation of Kinetic Parameters 
   Data were expressed as mean ± S.E.M. Student’s t-test was used for statistical 
analysis, with p < 0.05 as the criterion of significance.  
   The rate constant for terminal phase in pharmacokinetic studies was calculated 
as a slope using the last two data points. The calculation was performed for individual 
animals. 
   Intestinal membrane permeability (µL/cm2) assessed in Ussing-type chamber 
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was estimated by dividing the amount appeared in the acceptor side by both surface area 
(1 cm2) and initial concentration in the donor side. The permeability of celiprolol was 
obtained by subtracting the permeability of FD-4 from that of celiprolol. 
   In the Uptake study with Xenopus laevis oocytes, cell-to-medium ratio was 
obtained by dividing the cellular uptake amount by the concentration of test compound 
in the medium. Kinetic parameters for transport activity were estimated by nonlinear 
least-squares fitting of all the concentration-dependent data to the following equation 
using the MULTI program: 
       V = Vmax x S/(Km + S) + Kns x S    (1) 
where V, S, Vmax, Km and Kns represent the initial uptake velocity, substrate 
concentration, maximum uptake velocity, Michaelis constant and non-saturable uptake 
clearance, respectively. Concentration-dependent inhibition of celiprolol uptake by BSP 
was fitted to the following equation: 
R = IC50
IC50 +  I       (2) 
where R is the uptake normalized by the control (without BSP) value, I is the BSP 
concentration and IC50 is the inhibition constant. 
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RESULTS 
Comparison of plasma concentration profile of celiprolol after oral administration 
between wild and mdr1a/b(-/-) mice 
 Involvement of P-gp as an efflux transport system for celiprolol has already 
been suggested by using P-gp inhibitor in rats 6, but there has been no direct 
demonstration using gene knockout mice. Therefore, we first compared plasma 
concentration profile of celiprolol after oral administration between wild and 
mdr1a/b(-/-) mice. In wild mice, plasma concentration of celiprolol after oral 
administration at 3 mg/kg was under the limit of quantification (< 3 ng/mL) at most of 
sampling points, whereas that in mdr1a/b(-/-) mice was much higher (Fig. 1). 
 
Inhibitory effect of BSP on intestinal absorption of celiprolol in mdr1a/b(-/-) mice 
 We next attempted to inhibit oral absorption of celiprolol by coadministration 
of transporter inhibitor to demonstrate involvement of influx (uptake) transporter(s) in 
small intestine. Since such inhibitor may also inhibit P-gp, the mdr1a/b(-/-) mice were 
used to avoid effect of P-gp on the intestinal absorption. BSP is a quite potent inhibitor 
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of various OATP family members with an inhibition constant of 0.3-20 µM 29, whereas 
BSP would stably exist inside the intestinal lumen due to its low gastrointestinal 
absorption demonstrated in rats 30. Coadministration of BSP at 30 mg/kg body wt 
decreased plasma concentration of celiprolol after oral absorption in mdr1a/b(-/-) mice 
(Fig. 1). This dose of BSP was chosen because of its maximum solubility in saline. On 
the other hand, BSP exhibited minimal effect on slope of the terminal phase (Fig. 1). 
The rate constant for terminal phase of celiprolol with or without BSP were 9.05 ± 0.84 
x 10-3 and 6.98 ± 1.19 x 10-3 min-1, respectively (mean ± S.E.M., n = 3-5), with no 
significant difference between the two groups. However, these values were based on 
only two data points, and further studies may be necessary for validation of the absolute 
values. In the present study, we did not calculate other pharmacokinetic parameters 
because only four data points were available in wild mice.  
 
BSP inhibits small intestinal permeability of celiprolol  
 To demonstrate that inhibition of oral absorption of celiprolol by BSP occurs 
at the permeability process in small intestinal tissues, similar inhibition study was also 
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performed in Ussing-type chamber. Permeability of celiprolol from apical to basal side 
of small intestinal tissues obtained from the mdr1a/b(-/-) mice was much higher than that 
of FD-4, and reduced in the presence of BSP (Fig. 2). Appearance of FD-4 was also 
measured as a paracellular marker, and permeability of celiprolol was obtained by 
subtracting that of FD-4. The permeability of FD-4 in the absence or presence of BSP 
was 4.41 ± 1.58 and 5.81 ±1.30 µL/cm2 at 120 min, respectively. 
 
Celiprolol and other ß-blockers are substrates of small intestinal transporter 
OATP-A 
 OATP-A was recently clarified to be expressed on apical membranes of small 
intestine and proposed to be involved in intestinal absorption of therapeutic agents 18,19. 
On the other hand, OATP-B was also reported to be expressed on apical membranes of 
human small intestine and Caco-2 cells 23,31,32. As a candidate of oral absorption 
mechanism for celiprolol in vivo, we examined possible transport of celiprolol and other 
ß-blockers in Xenopus Laevis oocytes injected with cRNA for OATP-A or water. First, 
uptake of a mixture of the 11 ß-blocker (50 µM of each) by the oocytes was screened, 
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and then the initial concentration was decreased either to be 0.1, 1 or 50 µM, based on 
the limit of quantification of each compound, so that apparent uptake of each compound 
by oocytes injected with water can be detected (Fig. 3). The uptake of acebutolol, 
atenolol, celiprolol, nadolol, labetalol and sotalol by oocytes injected with cRNA for 
OATP-A increased in a time-dependent manner and was much higher than that in 
oocytes injected with water (Fig. 3). 
 Concentration-dependent uptake of celiprolol alone was then measured in the 
oocytes. The uptake of celiprolol by OATP-A-injected oocytes was much higher than 
that in water-injected oocytes (Fig. 4A). Eadie-Hofstee plot for OATP-A-mediated 
uptake, which was obtained by subtracting the uptake in the water-injected oocytes from 
that in OATP-A-injected oocytes, exhibited biphasic saturation (Fig. 4B). The Km, 
Vmax and Kns were estimated to be 20.5 ± 7.1 µM, 2.83 ± 0.69 pmol/oocyte/90 min 
and 9.12 ± 1.81 nL/oocyte/90 min, respectively. The cell-to-medium ratio of celiprolol 
at 60 µM was 39.7 nL/oocytes/90 min in OATP-A-injected oocytes (Fig. 4A), which 
was comparable with that observed in the cassette dosing study shown in Fig. 3 (~40.2 
nL/oocyte/90 min). The OATP-A-mediated uptake of celiprolol was concentration- 
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dependently decreased in the presence of BSP with the IC50 value of 32.5 ± 5.5 µM (Fig. 
4C). The uptake of celiprolol by water-injected oocytes also exhibited saturation, and 
this would be the reason for the discrepancy in absolute values for the uptake by 
water-injected oocytes between Fig. 3A (~ 4 nL/oocyte/90 min at 50 µM) and Table 1 (~ 
34 nL/oocyte/90 min at 1 µM). Although the reason for such saturation was unknown, 
there may be some endogenous binding sites and/or transporters for celiprolol in the 
oocytes. 
 The uptake of celiprolol by oocytes injected with cRNA for another small 
intestinal OATP, OATP-B was much lower than in OATP-A-injected oocytes (Table 1). 
On the other hand, the uptake of [3H]E3S was much higher in OATP-A and 
OATP-B-injected oocytes, compared with water-injected ones (Table 1). 
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DISCUSSION 
Possible involvement of influx transporters in gastrointestinal absorption has 
recently been suggested for several therapeutic agents. Especially, both OATP-A and 
OATP-B are expressed on apical membrane of small intestine in human and proposed to 
be involved in uptake of several anionic compounds 18,19,23. On the other hand, 
molecular mechanism involved in uptake of ß-blockers from apical side has not yet 
been identified despite that they have been widely used as oral drugs. Recent 
observation that citrus juice inhibits oral absorption of acebutolol, atenolol, celiprolol 
and talinolol may imply similar involvement of OATP transporter(s) in the absorption of 
ß-blockers 11-15, as suggested for fexofenadine case 18,19. However, such inhibition study 
in vivo may be affected by other factors than the membrane permeation process. 
Therefore, more detailed studies focusing on the uptake process of ß-blockers from 
apical membranes of small intestine is also important for understanding the molecular 
mechanism lying on their gastrointestinal absorption, and experimental animal models 
could be one of useful tools for such purpose. In the present study we used mdr1a/b(-/-) 
mice to analyze the influx process of ß-blockers with avoiding any effect of P-gp. This 
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would probably be appropriate because plasma concentration of celiprolol was much 
higher in mdr1a/b(-/-) mice, compared with wild mice, after oral administration (Fig. 1), 
indicating predominant role of P-gp as an efflux transport system for celiprolol. The 
dose of celiprolol (3 mg/kg) is comparable with the clinical dose in human (100~400 
mg/body). This finding could be compatible with the clinical observation of the 
drug-drug interactions for ß-blockers via the small intestinal P-gp 11,33. However, P-gp is 
expressed in various tissues other than the small intestine. Celiprolol is mainly excreted 
into the urine as an unchanged form after oral absorption1,20,21, with minor contribution 
of metabolism to the systemic clearance. Therefore, not only the intestinal absorption, 
but also the distribution and/or renal elimination of celiprolol may be affected by 
mdr1a/b gene knockout. 
In mdr1a/b(-/-) mice, coadministration of transporter inhibitor, BSP 
substantially decreased oral absorption of celiprolol (Fig. 1). Since anesthesia might 
affect intestinal absorption 34, and experimental results obtained in vivo alone does not 
necessarily lead to any conclusion regarding the inhibition of celiprolol transport by 
BSP, Ussing-type chamber studies were then performed as another intestinal absorption 
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experiment with an aim to more directly assess the effect of BSP on intestinal 
permeability of celiprolol. BSP also inhibited intestinal membrane permeability of 
celiprolol in Ussing-type chamber (Fig. 2), suggesting the influx transport process for 
celiprolol in mouse small intestine. It would be noteworthy that anionic compound BSP 
inhibits the uptake of a cationic compound celiprolol. Intestinal transport mechanism for 
celiprolol may thus have unique recognition specificity.  
Because BSP substantially inhibited gastrointestinal absorption of celiprolol 
(Figs. 1, 2), we speculated that OATP family would be one of candidate transporters 
responsible for the uptake of celiprolol. Immunohistochemical analysis has revealed that 
both OATP-A and OATP-B are localized on apical membrane of human intestinal 
epithelial cells or Caco-2 cells 19,23,31. Therefore, Xenopus Laevis oocytes injected with 
cRNA for each transporter were used to clarify whether celiprolol is their substrate or 
not. The present finding demonstrates that celiprolol is efficiently transported by 
OATP-A, compared with OATP-B (Fig. 3, 4, 5, Table 1). The OATP-A-mediated uptake 
of celiprolol exhibited saturation and biphasic transport (Fig. 4). Although the reason for 
biphasic transport is unknown, one of the possible explanations could be the presence of 
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multiple recognition sites within OATP-A molecule. Actually, similar biphasic uptake 
has been reported in the case of OATP-C mediated estron-3-sulfate transport 35. 
Interestingly, other ß-blockers including acebutolol, atenolol, labetalol, nadolol and 
sotalol were also identified to be the substrates of OATP-A in the present study (Fig. 3), 
and citrus juice inhibited oral absorption of at least acebutolol, atenolol and celiprolol in 
human 11-15. It was also reported that gastrointestinal absorption of sotalol was inhibited 
by coadministration of thlithromycin 17. Thus, substantial transport by OATP-A of 
ß-blockers (Fig. 3) seems well compatible with the drug-food or drug-drug interaction, 
and OATP-A would be one of the possible transporters involved in influx of celiprolol 
from apical membrane in human small intestine. All the ß-blockers transported by 
OATP-A have basic pKa values (9~10) except that both labetalol and sotalol also have 
pKa of 7~8. Therefore, OATP-A could have broad substrate specificity, not only for 
anionic compounds, but also cationic ones. 
  The uptake study in OATP-A-injected oocytes revealed the presence of 
saturable transport component for celiprolol by OATP-A with Km of ~ 20 µM (Fig. 4B). 
On the other hand, the concentration of celiprolol (100 µM) in the Ussing-type chamber 
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studies was higher than the Km value of OATP-A-mediated celiprolol uptake. Therefore, 
the uptake system for celiprolol in mouse small intestine might be saturated if the Km 
value for celiprolol uptake in mouse small intestine is similar to that of human OATP-A. 
This would be one of the possible reasons for the present finding that inhibitory effect 
of BSP was not so obvious, the effect at 100 µM BSP being not significant in the 
Ussing-type chamber studies (Fig. 2). 
Up to now, BSP is known to be recognized by various human OATPs such as 
OATP-A, OATP-B, OATP-C, OATP-8 and OATP-F 36. BSP is preferentially transported 
by OATP-C rather than OATP-8 37,38. Therefore, BSP may affect these OATPs 
expressed in various tissues other than small intestine, and further studies are required 
to clarify possible effect of BSP on distribution and/or elimination of celiprolol after 
oral absorption. Uptake transporters such as OATP-C and OATP-8 are thought to be 
liver-specific, whereas OATP-A and OATP-B are expressed in the intestine 19. Therefore, 
uptake studies in Xenopus Laevis oocytes were performed for OATP-A and OATP-B in 
the present study. However, the liver-specific expression alone does not necessarily 
exclude the possibility that small level of intestinal expression may be enough to be 
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involved in intestinal handling of therapeutic agents. It is essentially important to clarify 
which OATP member is actually involved in intestinal absorption of celiprolol in 
humans, but the demonstration of such contribution of each transporter protein is quite 
difficult due to the limitation of experimental systems using freshly isolated human 
intestinal tissues. Therefore, the present finding alone has limitation to discuss the 
possible contribution of OATP-A to intestinal absorption of celiprolol in human, and 
further studies are required to finally demonstrate involvement of the transporter(s). 
 In the present study, oocytes were incubated with a mixture of several 
ß-blockers as a first screening to identify OATP-A substrates (Fig. 3). Doing such a 
cassette incubation for transporters studies, however, raises the concern for possible 
interactions. In the present study, some of ß-blockers with higher detection sensitivity in 
LC-MS/MS were set to be lower (0.1 or 1 µM) concentration with an aim to minimize 
possible interactions via the transporter. The cell-to-medium ratio of celiprolol at 60 µM 
in single dosing study was 39.7 nL/oocye/90 min in OATP-A-injected oocytes (Fig. 4A), 
which was comparable with that observed in the cassette dosing study at 50 µM of 
celiprolol (~ 40.2 nL/oocyte/90 min, Fig. 3), suggesting minimal interaction for the 
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uptake of celiprolol. However, this does not necessarily exclude the possibility of the 
interaction among the other ß-blockers. Further uptake studies using a single ß-blocker 
are needed to compare the absolute transport activity by OATP-A among the ß-blockers. 
In addition, it would be noteworthy that interaction due to the cassette dosing may 
hinder the identification of transporter substrates. 
Taylor et al. (1985) reported that hydrophilic ß-blockers including acebutolol, 
nadolol, atenolol and sotalol (with logP values from 1.87 to -0.79) exhibit almost similar 
absorption rate constants in rats, and their oral absorption does not follow pH-partition 
theory 3. They have proposed characteristics of aqueous phase transport, possibly via 
membrane pores, for such hydrophilic ß-blockers. Although the contribution of such 
paracellular route cannot be fully neglected, the present finding demonstrates 
involvement of influx transporters at least for celiprolol. Actually, BSP minimally 
affected intestinal permeability of FD-4 (see legends to Fig. 2), suggesting minimal 
effect of BSP on the paracellular route.  
In conclusion, the present study has suggested that P-gp is involved in 
gastrointestinal absorprion of celiprolol in mice. We have also obtained direct evidence 
- 28 - 
that gastrointestinal absorption of celiprolol is mediated by influx transporter(s). The 
mdr1a/b(-/-) mice could be an useful tool to identify and characterize the influx transport 
system(s) for therapeutic agents with avoiding effect of P-gp-mediated efflux. As one of 
intestinal influx transporter, OATP-A transports several ß-blockers. 
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LEGENDS TO FIGURES 
Fig. 1  Plasma concentration-time profile of celiprolol in wild (closed circles) and 
mdr1a/b(-/-) mice with (open triangles) or without (open circles) BSP after an oral 
dose (3 mg/kg) of celiprolol. 
 Celiprolol (3 mg/5 mL/kg body wt) with or without BSP (30 mg/5 mL/kg 
body wt) was orally administered in wild and mdr1a/b(-/-) mice, and plasma 
concentration of celiprolol was determined by LC-MS/MS. Plasma concentration in 
wild mice at 5, 240 and 360 min was also measured, but was under the limit of 
quantification (< 3 ng/mL). Each value represents the mean ± S.E.M. (n = 3-5). 
*, Significantly different from mdr1a/b(-/-) mice in the absence of BSP (p < 0.05). 
 
Fig. 2  Effect of BSP on permeability of celiprolol across isolated mouse intestinal 
tissues. 
Celiprolol (100 µM) with FD-4 (100 µM) was added into apical side of small 
intestinal tissues in Ussing-type chamber, and appearance in basal side was measured by 
LC-MS/MS in the absence (closed circles) or presence of 100 µM (open circles) or 7.5 
- 40 - 
mM (open triangles) of BSP. Appearance of FD-4 was also measured as a paracellular 
marker, and permeability of celiprolol was obtained by subtracting that of FD-4. The 
permeability of FD-4 in the absence or presence of BSP was 4.41 ± 1.58 and 5.81 ± 
1.30 µL/cm2 at 120 min, respectively. Each value represents the mean ± S.E.M. (n = 4). 
*, Significantly different from mdr1a/b(-/-) mice in the absence of BSP (p < 0.05). 
 
Fig. 3  Time profiles of the uptake of ß-blockers by Xenopus laevis oocytes 
expressing OATP-A. 
  The oocytes injected with cRNA for OATP-A (closed circles) or water alone 
(open circle) were incubated with a mixture of 50 µM of celiprolol (A), acebutolol (B), 
atenolol (C), nadolol (D) and sotalol (E), 1 µM of labetalol (F) and oxprenolol (G), 0.1 
µM of alprenolol (H), metoprolol (I), pindolol (J) and propranolol (K) at 25ºC. Uptake 
of each compound was simultaneously measured by LC-MS/MS. Each value represents 
the mean ± S.E.M. (n = 7-8). 
*, Significantly different from oocytes injected with water (p < 0.05). 
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Fig. 4  Concentration dependence of celiprolol uptake (A, B) and inhibition by 
BSP of the celiprolol uptake (C) by Xenopus laevis oocytes expressing OATP-A. 
  In panel A, uptake of celiprolol (1 – 3,000 µM) for 90 min was determined at 
25ºC in oocytes injected with cRNA for OATP-A (closed circles) or water (open circle). 
In panel B, OATP-A-mediated uptake was obtained by subtracting the uptake by 
water-injected oocytes from that by oocytes expressing OATP-A, and shown as 
Eadie-Hofstee plot in which the straight line indicates fitted one. In panel C, the 
OATP-A-mediated uptake was measured in the presence of various concentrations of 
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 Table 1   Uptake of celiprolol and [3H]E3S by OATP-A and OATP-B 
Uptake (nL / oocyte / 90 min) 
Compound 
OATP-A OATP-B Water 
Celiprolol 108 ± 19* 45.7 ± 1.6 33.8 ± 4.8 
[3H]E3S 5.26 ± 1.4 x 103* 7.05 ± 0.69 x 103* 388 ± 41 
Oocytes injected with cRNA for OATP-A, OATP-B or water were incubated with 
celiprolol (1.0 µM) or [3H]E3S (9.4 nM) for 90 min, and uptake was determined. Data 
were expressed as mean ± SEM (n=8). *, Significantly different from oocytes injected 
with water (p < 0.05). 
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